一项对两项II期试验中接受贝伐单抗和培美曲塞作为二线治疗的晚期非鳞状非小细胞肺癌且脑转移病情稳定患者的汇总分析。
A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy.
作者信息
Gubens Matthew A, Chuang Jody C, Akerley Wallace, Langer Corey J, Clément-Duchêne Christelle, San Pedro-Salcedo Melanie, Colevas A Dimitrios, Dragnev Konstantin, Socinski Mark A, Wakelee Heather A
机构信息
Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, CA, USA.
Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.
出版信息
J Thorac Dis. 2018 Jan;10(1):219-227. doi: 10.21037/jtd.2017.12.30.
Abstract
BACKGROUND
Brain metastases are a common complication of advanced non-small cell lung cancer (NSCLC). Patients with brain metastases were excluded from the registration trials of bevacizumab that showed a survival benefit with the use of angiogenesis inhibition.
METHODS
In this study, we pooled data from two separate trials designed to evaluate the risk of central nervous system (CNS) hemorrhage in patients with stable treated brain metastases to look specifically at both the safety and efficacy of bevacizumab and pemetrexed when used as second-line treatment in NSCLC patients with stable treated brain metastases.
RESULTS
We report acceptable safety and promising efficacy from our analysis.
CONCLUSIONS
Our study adds further evidence of safety of administering pemetrexed and bevacizumab to patients with stable brain metastases. There is increasing roles for systemic therapies to treat stable brain metastases for patients with advanced NSCLC.
摘要
背景
脑转移是晚期非小细胞肺癌（NSCLC）的常见并发症。脑转移患者被排除在贝伐单抗的注册试验之外，该试验显示使用血管生成抑制可带来生存获益。
方法
在本研究中，我们汇总了两项独立试验的数据，这些试验旨在评估经治疗病情稳定的脑转移患者发生中枢神经系统（CNS）出血的风险，以专门研究贝伐单抗和培美曲塞在病情稳定的NSCLC脑转移患者中用作二线治疗时的安全性和疗效。
结果
我们的分析显示安全性可接受且疗效有望令人满意。
结论
我们的研究进一步证明了对病情稳定的脑转移患者给予培美曲塞和贝伐单抗的安全性。对于晚期NSCLC患者，全身治疗在治疗病情稳定的脑转移方面发挥着越来越重要的作用。
相似文献
1
A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy.一项对两项II期试验中接受贝伐单抗和培美曲塞作为二线治疗的晚期非鳞状非小细胞肺癌且脑转移病情稳定患者的汇总分析。
J Thorac Dis. 2018 Jan;10(1):219-227. doi: 10.21037/jtd.2017.12.30.
2
Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.培美曲塞-铂类双药化疗联合或不联合贝伐珠单抗作为中国未经治疗的晚期非鳞状非小细胞肺癌患者一线治疗的疗效比较。
Clin Ther. 2019 Mar;41(3):518-529. doi: 10.1016/j.clinthera.2019.02.004. Epub 2019 Mar 4.
3
Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.贝伐单抗在非小细胞肺癌合并脑转移患者中的安全性。
J Clin Oncol. 2009 Nov 1;27(31):5255-61. doi: 10.1200/JCO.2009.22.0616. Epub 2009 Sep 8.
4
Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015.培美曲塞联合贝伐单抗用于老年晚期或复发性非鳞状非小细胞肺癌一线化疗的可行性研究：TORG1015
BMC Cancer. 2016 May 12;16:306. doi: 10.1186/s12885-016-2338-6.
5
Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases.贝伐单抗、培美曲塞和卡铂用于非小细胞肺癌患者的一线治疗：聚焦脑转移患者。
Oncol Lett. 2016 Dec;12(6):4635-4642. doi: 10.3892/ol.2016.5268. Epub 2016 Oct 17.
6
Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).贝伐珠单抗联合或不联合培美曲塞维持治疗在一线贝伐珠单抗联合顺铂和培美曲塞诱导治疗后晚期非鳞状非小细胞肺癌中的随机 III 期临床试验：AVAPERL（MO22089）。
J Clin Oncol. 2013 Aug 20;31(24):3004-11. doi: 10.1200/JCO.2012.42.3749. Epub 2013 Jul 8.
7
Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer.卡铂/培美曲塞联合或不联合贝伐珠单抗治疗晚期非鳞状非小细胞肺癌的疗效比较。
J Natl Compr Canc Netw. 2019 May 1;17(5):469-477. doi: 10.6004/jnccn.2018.7102.
8
A Randomized Phase III Study of Pembrolizumab Versus Pembrolizumab-Carboplatin-Pemetrexed for Locally Advanced or Metastatic Nonsquamous Non-small-cell Lung Cancer with PD-L1 50% or more (LAPLACE-50): Study Protocol.一项评估帕博利珠单抗对比帕博利珠单抗联合卡铂和培美曲塞用于局部晚期或转移性非鳞状非小细胞肺癌（PD-L1 表达≥50%）的随机 III 期临床研究（LAPLACE-50）：研究方案。
Clin Lung Cancer. 2021 Nov;22(6):e921-e924. doi: 10.1016/j.cllc.2021.02.008. Epub 2021 Feb 19.
9
[Efficacy and Safety of Bevacizumab Combined with Chemotherapy as Second-line or Later-line Treatment in Advanced Nonsquamous Non-small Cell Lung Cancer].贝伐单抗联合化疗作为晚期非鳞状非小细胞肺癌二线或更后线治疗的疗效与安全性
Zhongguo Fei Ai Za Zhi. 2018 Jul 20;21(7):513-518. doi: 10.3779/j.issn.1009-3419.2018.07.02.
10
Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer.贝伐珠单抗治疗非小细胞肺癌脑转移患者的疗效和安全性。
J Neurooncol. 2010 Dec;100(3):443-7. doi: 10.1007/s11060-010-0200-2. Epub 2010 May 4.
引用本文的文献
1
A review on intrathecal administration of medications for leptomeningeal metastases in solid tumors.实体瘤软脑膜转移鞘内给药的综述
Front Pharmacol. 2025 Feb 4;16:1472945. doi: 10.3389/fphar.2025.1472945. eCollection 2025.
2
DD-PRiSM: a deep learning framework for decomposition and prediction of synergistic drug combinations.DD-PRiSM：一种用于协同药物组合分解与预测的深度学习框架。
Brief Bioinform. 2024 Nov 22;26(1). doi: 10.1093/bib/bbae717.
3
Erlotinib plus bevacizumab versus erlotinib alone in patients with -positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials.厄洛替尼联合贝伐珠单抗对比厄洛替尼单药治疗表皮生长因子受体阳性的晚期非小细胞肺癌的随机对照临床试验的系统评价和荟萃分析。
BMJ Open. 2022 Aug 19;12(8):e062036. doi: 10.1136/bmjopen-2022-062036.
4
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive -mutant Non-small Cell Lung Cancer.雷莫芦单抗联合奥希替尼治疗晚期 T790M 阳性突变型非小细胞肺癌的 I 期研究。
Clin Cancer Res. 2021 Feb 15;27(4):992-1002. doi: 10.1158/1078-0432.CCR-20-1690. Epub 2020 Oct 12.
5
First-line pemetrexed and carboplatin plus anlotinib for epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative lung adenocarcinoma with brain metastasis: A case report and review of the literature.一线培美曲塞、卡铂联合安罗替尼治疗表皮生长因子受体野生型和间变性淋巴瘤激酶阴性且伴有脑转移的肺腺癌：一例报告并文献复习
Medicine (Baltimore). 2020 Sep 4;99(36):e22128. doi: 10.1097/MD.0000000000022128.
6
A patient with anaplastic lymphoma kinase-positive non-small cell lung cancer with development of leptomeningeal carcinomatosis while on targeted treatment with crizotinib.ALK 阳性非小细胞肺癌患者在接受克唑替尼靶向治疗时发生脑膜转移。
J Natl Compr Canc Netw. 2013 Apr 1;11(4):389-94. doi: 10.6004/jnccn.2013.0054.
本文引用的文献
1
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.阿特珠单抗对比多西他赛用于既往治疗过的非小细胞肺癌患者（OAK）：一项3期、开放标签、多中心随机对照试验
Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.
2
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
3
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases.非小细胞肺癌（NSCLC）患者中，未治疗或病情进展的中枢神经系统转移患者对纳武单抗的颅内反应。
Lung Cancer. 2016 Aug;98:114-117. doi: 10.1016/j.lungcan.2016.05.031. Epub 2016 May 31.
4
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.帕博利珠单抗用于治疗黑色素瘤或非小细胞肺癌且伴有未经治疗的脑转移患者：一项非随机、开放标签的2期试验的早期分析
Lancet Oncol. 2016 Jul;17(7):976-983. doi: 10.1016/S1470-2045(16)30053-5. Epub 2016 Jun 3.
5
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.阿特珠单抗对比多西他赛用于治疗既往接受过治疗的非小细胞肺癌患者（POPLAR）：一项多中心、开放标签、2 期随机对照临床试验。
Lancet. 2016 Apr 30;387(10030):1837-46. doi: 10.1016/S0140-6736(16)00587-0. Epub 2016 Mar 10.
6
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.帕博利珠单抗对比多西他赛用于治疗后 PD-L1 阳性的、晚期非小细胞肺癌（KEYNOTE-010）：一项随机对照试验。
Lancet. 2016 Apr 9;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.
7
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
8
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.纳武单抗与多西他赛治疗晚期鳞状细胞非小细胞肺癌的疗效比较
N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
9
Pembrolizumab for the treatment of non-small-cell lung cancer.帕博利珠单抗治疗非小细胞肺癌。
N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.
10
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.克唑替尼治疗晚期ALK重排非小细胞肺癌合并脑转移患者的临床经验
J Clin Oncol. 2015 Jun 10;33(17):1881-8. doi: 10.1200/JCO.2014.59.0539. Epub 2015 Jan 26.
Zotero 插件